– Early clinical data of naked monoclonal antibodies support safety of targeting anti-Müllerian hormone receptor 2 (AMHR2), an oncology target of interest ̶
– Antibody-drug conjugates (ADCs) targeting AMHR2 could provide clinical efficacy in gynecologic, colorectal and other forms of cancer ̶
ALAMEDA, Calif. and TOULOUSE, France – May 4, 2021 – Exelixis, Inc. (Nasdaq: EXEL) and GamaMabs Pharma SA today announced that they have entered into an agreement under which Exelixis will, upon the future closing of the asset purchase and subject to certain conditions to closing, acquire all rights, title and interest in GamaMabs’ AMHR2 antibody technology. Exelixis will pay GamaMabs $5 million upon signing of the agreement, make additional payments upon completion of closing conditions, and make additional milestone payments after closing, contingent upon various events. Once the transfer is completed, Exelixis will control 100% of GamaMabs’ AMHR2 franchise technology including all assets pertaining to GamaMabs’ monoclonal antibody drug product murlentamab (GM-102). Read more
Toulouse and Paris, August 31, 2020
GamaMabs is deeply saddened to learn the death of Isabelle Tabah-Fisch, its former Chief Medical Officer, on August 28.
Isabelle joined GamaMabs Pharma in November 2016 to bring us her remarkable expertise in Oncology and her high-level network which enabled her to design and implement our clinical trials, until her retirement in March 2020.
Despite the illness that affected her for two years, Isabelle displayed admirable professionalism, courage and energy.
Beyond her professional qualities, we will always remember Isabelle’s great vitality, her joie de vivre, her motivation for therapeutic progress and her ethical standards.
Our hearts go out to Isabelle’s family, especially her father and 3 children.
May Isabelle rest in peace.
Longer than expected PFS for murlentamab when combined with FTD/TPI, particularly in patients with medium/high AMHRII expression, along with immune cascade activation in the tumor micro-environment Read more
Objective responses, good safety and evidence of stimulation of the immune system observed under murlentamab (GM102) single agent and in combination with chemotherapy Read more
New clinical data in Granulosa Cell Tumor (GCT) patients will be presented at the EORTC–NCI–AACR 2018 Symposium and GM102 unique T-cell activation mechanism at the AACR 2018 Conference on Tumor Immunology and Immunotherapy
C201 phase 2 will study immuno-enhancer antibody GM102, targeting AMHRII as a single agent and in combination with Trifluridine/Tipiracil (Lonsurf®)
Objective responses, good safety and evidence of stimulation of the immune system were observed with GM102 administered as a single agent in the dose-finding escalation part of the study
AMHRII expression and Antibody-Drug Conjugate preclinical data suggest potential broader applications for anti-AMHRII-based therapy
This designation has been awarded for the treatment of AMHR2-expressing ovarian cancers, exclusive of AMHR2-expressing fallopian tube cancers and primary peritoneal cancers
First in class anti-AMHRII monoclonal antibody is currently completing early clinical phases in ovarian cancer